Palisade Bio Doses First Patient in Phase 2b Ulcerative Colitis Trial

Medical professional displaying a digital illustration of the human digestive system with healthcare icons, representing research and treatment development for ulcerative colitis.

Key Points

  • Palisade Bio has dosed the first patient in ASCENTRA-UC, a Phase 2b study of once-daily oral PALI-2108.
  • The randomized, placebo-controlled trial plans to enroll approximately 204 patients with moderately to severely active ulcerative colitis.
  • The primary endpoint is clinical remission at Week 12, with induction topline results expected in the fourth quarter of 2027.
  • Palisade has activated 29 of 30 planned U.S. sites and is working toward approximately 115 sites globally.
  • Earlier clinical findings were preliminary and uncontrolled; the Phase 2b study will test whether those signals translate into benefit against placebo.

 

Palisade Bio (NASDAQ: PALI) has begun patient dosing in ASCENTRA-UC, advancing its investigational PDE4 inhibitor prodrug into a larger, controlled study.

The milestone marks the start of treatment in the trial—not evidence that PALI-2108 is effective in this patient population.

Study Tests Two Oral Doses Against Placebo

ASCENTRA-UC is a global, multicenter, randomized, double-blind Phase 2b trial evaluating once-daily PALI-2108 at 15 mg and 30 mg against placebo.

The primary endpoint is clinical remission at Week 12, measured by the Modified Mayo Score. Key secondary endpoints include:

  • Clinical response.
  • Endoscopic improvement.
  • Histologic-endoscopic mucosal improvement.

After the 12-week induction period, eligible patients can continue into a 36-week maintenance phase to assess durability of response through Week 48. The expected fourth-quarter 2027 readout concerns induction results, not the completed maintenance phase.

Prodrug Design Targets Gut Activation and Tolerability

PALI-2108 is designed to activate in the terminal ileum and colon. Its intended pharmacologic profile combines high intestinal tissue exposure with sustained systemic exposure.

Palisade aims to retain the anti-inflammatory activity of PDE4 inhibition while potentially reducing tolerability limitations associated with systemic drugs in the class. That tolerability advantage remains a development objective rather than an established comparative finding.

The company reported that its completed Phase 1 program was generally well tolerated, with no serious adverse events.

Earlier Activity Came From a Five-Patient Exploratory Cohort

In a small, open-label Phase 1b ulcerative colitis cohort, five patients received seven days of treatment. All five evaluable patients achieved clinical response, and two achieved clinical remission based on the modified Mayo Score.

Those results provide an early signal, but the small sample, short treatment period and absence of a placebo group limit what can be concluded. ASCENTRA-UC is designed to evaluate efficacy and safety more rigorously in a larger population.

Global Site Expansion Supports Enrollment

Palisade has activated 29 of its 30 planned U.S. sites. It is also progressing toward approximately 115 sites worldwide, with clinical trial application clearance in Canada and submissions under review in Europe and other international countries.

Site activation supports recruitment capacity, but it is distinct from patient enrollment. The company has not provided an enrollment completion date or a patient count beyond the first dosing milestone.

Investor Takeaway: Trial Execution Becomes the Focus

For PALI investors, first-patient dosing moves the program into its next clinical testing stage. The principal scheduled catalyst is the Week 12 induction readout expected in the fourth quarter of 2027.

The central questions are whether either dose improves remission rates versus placebo, whether tolerability supports continued treatment, and whether responses persist during maintenance. The early Phase 1 findings do not yet resolve those questions.

 

Share this article:

About the Author:

Zura Halts Skin Disease Program After Phase 2 Setback, Continues Two Other Studies

Alex Corbit

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup